StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Outlook Therapeutics's profit margin for the twelve months ending Sep 30, 2019 was -423.8%. For fiscal 2025 it was -4416.2%, against -423.8% the year before. The highest annual figure on record is -423.8% in fiscal 2019.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Sep 30, 2025-4416.2%−3992.4
FY2019Sep 30, 2019-423.8%+550.8
FY2018Sep 30, 2018-974.6%+44.6
FY2017Sep 30, 2017-1019.3%+769.7
FY2016Sep 30, 2016-1788.9%−880.9
FY2015Sep 30, 2015-908.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2025CQ2 2025Jun 30, 2025-1338.8%−426.2
Q4 FY2019CQ3 2019Sep 30, 2019-172.5%+1408.0
Q3 FY2019CQ2 2019Jun 30, 2019-760.6%+331.8
Q2 FY2019CQ1 2019Mar 31, 2019-1597.9%−621.1
Q1 FY2019CQ4 2018Dec 31, 2018-912.5%−663.7
Q4 FY2018CQ3 2018Sep 30, 2018-1580.5%−1360.9
Q3 FY2018CQ2 2018Jun 30, 2018-1092.4%+666.3
Q2 FY2018CQ1 2018Mar 31, 2018-976.8%+1677.4
Q1 FY2018CQ4 2017Dec 31, 2017-248.8%+6051.4
Q4 FY2017CQ3 2017Sep 30, 2017-219.6%+1915.8
Q3 FY2017CQ2 2017Jun 30, 2017-1758.7%+2752.8
Q2 FY2017CQ1 2017Mar 31, 2017-2654.2%−2298.2
Q1 FY2017CQ4 2016Dec 31, 2016-6300.2%–
Q4 FY2016CQ3 2016Sep 30, 2016-2135.4%–
Q3 FY2016CQ2 2016Jun 30, 2016-4511.6%–
Q2 FY2016CQ1 2016Mar 31, 2016-356.1%–

More Outlook Therapeutics figures

See a number that looks wrong?